---
title: "Keen Vision Acquisition | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265583823.md"
datetime: "2025-11-12T21:03:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265583823.md)
  - [en](https://longbridge.com/en/news/265583823.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265583823.md)
generator: "portal-rs"
---

# Keen Vision Acquisition | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EBIT: As of FY2025 Q3, the actual value is USD -248.48 K.

### Segment Revenue

-   The company has not generated any operating revenues as of September 30, 2025, and will not generate any until after the completion of a Business Combination.

### Operational Metrics

-   **Net Income**: For the nine months ended September 30, 2025, net income was $1,499,692, compared to $6,600,651 for the same period in 2024.
-   **Formation and Operating Costs**: For the nine months ended September 30, 2025, formation and operating costs were $611,853, compared to $1,039,445 for the same period in 2024.
-   **Dividend Income**: For the nine months ended September 30, 2025, dividend income earned in investments held in the Trust Account was $2,111,544, compared to $5,596,106 for the same period in 2024.
-   **Interest Income**: For the nine months ended September 30, 2025, interest income earned in investments held in the Trust Account was $2,043,965.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities was - $664,463 for the nine months ended September 30, 2025, compared to - $681,249 for the same period in 2024.
-   **Investing Cash Flow**: Net cash provided by investing activities was $16,457,732 for the nine months ended September 30, 2025.
-   **Financing Cash Flow**: Net cash used in financing activities was - $15,831,937 for the nine months ended September 30, 2025, compared to $90,000 provided by financing activities for the same period in 2024.

### Unique Metrics

-   **Cash and Investments Held in Trust Account**: As of September 30, 2025, the company had $56,026,877 in cash and investments held in the Trust Account, compared to $70,373,065 as of December 31, 2024.
-   **Accrued Expenses**: As of September 30, 2025, accrued expenses were $38,746, compared to $97,813 as of December 31, 2024.
-   **Extension Promissory Note Payable**: As of September 30, 2025, the extension promissory note payable was $2,234,011, compared to $600,000 as of December 31, 2024.
-   **Amount Due to a Related Party**: As of September 30, 2025, the amount due to a related party was $1,200,880, compared to $575,085 as of December 31, 2024.

### Future Outlook and Strategy

#### Core Business Focus

-   The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses or entities. The company will focus on businesses in the biotechnology, consumer goods, and agriculture sectors.
-   The company has entered into a merger agreement with Medera Inc., a clinical stage biopharmaceutical company, and plans to complete the business combination by November 27, 2025, unless further extended.

#### Non-Core Business

-   The company has not commenced any operations and all activities through September 30, 2025, relate to the company’s formation, the initial public offering, and activities necessary to identify a potential target and prepare for a Business Combination.

#### Priority

-   The company has extended the time available to complete a business combination multiple times by depositing additional funds into the Trust Account. The company now has until November 27, 2025, to consummate a business combination.

### Related Stocks

- [KVAC.US](https://longbridge.com/en/quote/KVAC.US.md)
- [KVACF.US](https://longbridge.com/en/quote/KVACF.US.md)

## Related News & Research

- [Nvidia has lost $2 trillion in value. Here's what options traders expect from earnings](https://longbridge.com/en/news/305815593.md)
- [MPs ask what the break clause was for as Palantir wins two more years in the NHS](https://longbridge.com/en/news/305803837.md)
- [Elizabeth Warren Targets CVS, UnitedHealth and Cigna, Says Healthcare Giants ‘Take a Cut at Every Step’ as She Calls for Breaking Up Conglomerates](https://longbridge.com/en/news/305798081.md)
- [Nvidia shares set for $335 billion swing after earnings, options show](https://longbridge.com/en/news/305809285.md)
- [Lumentum ranked among Forbes America’s Best Companies](https://longbridge.com/en/news/305716406.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**